.jetcityimage/iStock Content using Getty Images Morgan Stanley has decided on Eli Lilly (NYSE: LLY) as its own best biopharma selection for 2025 as well as rated yet another 9 labels in the area as obese. The expenditure bank said in a keep in mind that it continues to strongly believe “diabesity is readied to end up being.